956 related articles for article (PubMed ID: 29996082)
1. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
[TBL] [Abstract][Full Text] [Related]
2. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in
Bekker LG; Dintwe O; Fiore-Gartland A; Middelkoop K; Hutter J; Williams A; Randhawa AK; Ruhwald M; Kromann I; Andersen PL; DiazGranados CA; Rutkowski KT; Tait D; Miner MD; Andersen-Nissen E; De Rosa SC; Seaton KE; Tomaras GD; McElrath MJ; Ginsberg A; Kublin JG;
EClinicalMedicine; 2020 Apr; 21():100313. PubMed ID: 32382714
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON(®)-TB Gold (+) Kenyan adults without evidence of tuberculosis.
Walsh DS; Owira V; Polhemus M; Otieno L; Andagalu B; Ogutu B; Waitumbi J; Hawkridge A; Shepherd B; Pau MG; Sadoff J; Douoguih M; McClain JB;
Vaccine; 2016 May; 34(21):2430-2436. PubMed ID: 27026148
[TBL] [Abstract][Full Text] [Related]
5. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
[TBL] [Abstract][Full Text] [Related]
6. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
[TBL] [Abstract][Full Text] [Related]
7. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
Suliman S; Luabeya AKK; Geldenhuys H; Tameris M; Hoff ST; Shi Z; Tait D; Kromann I; Ruhwald M; Rutkowski KT; Shepherd B; Hokey D; Ginsberg AM; Hanekom WA; Andersen P; Scriba TJ; Hatherill M;
Am J Respir Crit Care Med; 2019 Jan; 199(2):220-231. PubMed ID: 30092143
[TBL] [Abstract][Full Text] [Related]
8. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4(+) T cell counts >350 cells/mm(3).
Churchyard GJ; Snowden MA; Hokey D; Dheenadhayalan V; McClain JB; Douoguih M; Pau MG; Sadoff J; Landry B
Vaccine; 2015 Apr; 33(15):1890-6. PubMed ID: 25698492
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
10. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.
Tameris M; Mearns H; Penn-Nicholson A; Gregg Y; Bilek N; Mabwe S; Geldenhuys H; Shenje J; Luabeya AKK; Murillo I; Doce J; Aguilo N; Marinova D; Puentes E; Rodríguez E; Gonzalo-Asensio J; Fritzell B; Thole J; Martin C; Scriba TJ; Hatherill M;
Lancet Respir Med; 2019 Sep; 7(9):757-770. PubMed ID: 31416768
[TBL] [Abstract][Full Text] [Related]
11. An in vitro functional assay to measure the biological activity of TB vaccine candidate H4-IC31.
Ming M; Bernardo L; Williams K; Kolattukudy P; Kapoor N; Chan LG; Pagnon A; Piras F; Su J; Gajewska B; Salha D; Gisonni-Lex L
Vaccine; 2019 May; 37(22):2960-2966. PubMed ID: 31010716
[TBL] [Abstract][Full Text] [Related]
12. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
[TBL] [Abstract][Full Text] [Related]
14. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
[TBL] [Abstract][Full Text] [Related]
15. A 2-Dose AERAS-402 Regimen Boosts CD8
Sivakumaran D; Blatner G; Bakken R; Hokey D; Ritz C; Jenum S; Grewal HMS
Front Immunol; 2021; 12():673532. PubMed ID: 34177914
[TBL] [Abstract][Full Text] [Related]
16. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.
Kagina BM; Tameris MD; Geldenhuys H; Hatherill M; Abel B; Hussey GD; Scriba TJ; Mahomed H; Sadoff JC; Hanekom WA; ; Mansoor N; Hughes J; de Kock M; Whatney W; Africa H; Krohn C; Veldsman A; Kany AL; Douoguih M; Pau MG; Hendriks J; McClainc B; Benko J; Snowden MA; Hokey DA
Vaccine; 2014 Oct; 32(45):5908-17. PubMed ID: 25218194
[TBL] [Abstract][Full Text] [Related]
17. A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation.
Aboutorabian S; Hakimi J; Boudet F; Montano S; Dookie A; Roque C; Ausar SF; Rahman N; Brookes RH
Hum Vaccin Immunother; 2015; 11(6):1449-55. PubMed ID: 25997147
[TBL] [Abstract][Full Text] [Related]
18. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
Skeiky YA; Dietrich J; Lasco TM; Stagliano K; Dheenadhayalan V; Goetz MA; Cantarero L; Basaraba RJ; Bang P; Kromann I; McMclain JB; Sadoff JC; Andersen P
Vaccine; 2010 Jan; 28(4):1084-93. PubMed ID: 19896449
[TBL] [Abstract][Full Text] [Related]
19. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity.
Billeskov R; Elvang TT; Andersen PL; Dietrich J
PLoS One; 2012; 7(6):e39909. PubMed ID: 22768165
[TBL] [Abstract][Full Text] [Related]
20. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
